Advantages
- The presence of tissue trigger channels in the TMT based experiment significantly increases the disease specific protein identifications in the other fluid channels.
- Ability to enrich for specific protein subsets, such as secreted proteins, phosphopeptides and other post translational modifications and membrane proteins.
- Due to the unbiased nature of the analysis, we report all proteins and associated PTM’s that are detectable, unlike antibody or aptamer/affimer based technologies where the data is biased to the make-up of the selected analysis panel.
- By using an upfront high abundance protein depletion stage, Super Depletion, we can quantify many more lower abundant proteins in plasma and serum.
- Multiplexing multiple samples in a single TMT based mass spectrometry run significantly increases the sensitivity of protein detection.
- Compatibility with a wide variety of sample matrices, including plasma, serum, cell lysates, CSF, exosomes etc.
- Available for human, rodent, monkey, pig and other higher animal species.
- With TMT, multiple samples can be analysed on one mass spectrometric run. Using a common reference channel per plex we can quantify samples from 14 to 100+ sample cohorts in multiple mass spectrometric runs.
- Analysis package includes full computational proteomic analysis and bioinformatics covering extensive data interpretation, pathway analysis and biological relevance.
Application | Service | Description |
---|---|---|
Functional Biomarker Discovery |
TMTcalibrator 11-plex
TMTcalibrator 18-plex
|
|
Targeted Biomarker Assays |
TMTcalibrator 11-plex
TMTcalibrator 18-plex
|
|
Magnifying the search for circulating Biomarkers
Looking for functional biomarkers (those related to relevant biology) in body fluids faces several challenges. Fluid-derived proteins are generally present at low concentrations, whilst higher abundance proteins restrict the amount we can load into mass spectrometers.
To overcome those limitations we invented TMTcalibrator where we use the isobaric labelling with TMT or TMTpro to mix sources enriched with biomarkers (e.g. diseased tissue lysates) and peripheral fluids (Figure 1). By adding the content of tissue and fluid channels in a single analytical sample we substantially increase visibility of highly relevant peptides and proteins and improve the rate of discovery of valuable biomarkers.
TMTcalibrator can be combined with other workflows such as phosphopeptide enrichment, peptidomics and triggering with synthetic peptides depending on your specific needs.
TMTcalibrator tissue-enhanced biomarker discovery. Inclusion of an excess of tissue-derived proteins (trigger/calibrant) in the TMTcalibrator workflow boosts the signal intensity of any homologous proteins in the peripheral fluid channels relative to more abundant peripheral fluid proteins not present in tissue. This selective amplification allows more tissue-derived proteins to be identified and quantified using the data-dependent acquisition method for unbiased biomarker discovery. Fluid concentrations are calculated relative to the tissue trigger and comparison of expression between clinical groups can then be determined using standard bioinformatics methods
Sample requirements for TMTcalibrator analysis (per 18-plex experiment)
Application |
Plasma/Serum (per sample) |
CSF (per sample) |
Tissue Trigger (total protein) |
---|---|---|---|
Standard LC-MS2 | 100ul | 250ul | 1.3 mg |
LC-MS2 with upfront Super Depletion | 250ul | Not applicable | 1.3 mg |
SysQuant phosphoproteomics |
Generally not applicable | 600ul | 7.4 mg |
Case studies:
- “Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates”. A Proteome Sciences paper co-authored with University of Gothenburg. Combined use of a brain trigger and phosphopeptide enrichment alongside standard proteomics to identify several thousand proteins and unique phosphorylation events related to Alzheimer’s disease biology that can be monitored in cerebrospinal fluid (CSF). This paper includes the first report of quantification for over 30 phosphorylation sites on Tau in Alzheimer’s disease and control individual CSF.
- “Combined tissue and fluid proteomics with Tandem Mass Tags® to identify low-abundance protein biomarkers of disease in peripheral body fluid: An Alzheimer’s Disease case study”. A Proteome Sciences authored paper co-authored with University of Gothenburg and University College London describing application of the TMTcalibrator approach to identify biomarkers of neuroinflammation through use of cultured microglial cells as the trigger in a human CSF cohort. Also demonstrates translational potential as mouse BV2 cells were used in this case.
- “A Novel Method For Discovery of Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis Using Extensive Depletion and TMTcalibrator™ Tissue-Enhanced Plasma Proteomics” A Proteome Sciences poster presentation co-authored with Pliant Therapeutics showing the powerful combination of combining a fibrotic lung tissue trigger and Super Depletion of abundant plasma proteins to quantify over 5,600 proteins in plasma, including analysis of post-translationally modified collagens.
An example report is available upon request.
For FAQ’s on Unbiased Protein Biomarker Discovery based Proteomics please follow this link.
What’s included |
|
Material required |
|
Typical turnaround time |
|